US 12,281,182 B2
Solid state forms of voclosporin
Pavel Kolesa, Hlubocec (CZ); Ladislav Cvak, Opava-Zlatniky (CZ); Alexandr Jegorov, Dobra Voda (CZ); and Katerina Ondruszova, Ostrava (CZ)
Assigned to ASSIA CHEMICAL INDUSTRIES LTD., Tel Aviv (IL)
Filed by TEVA PHARMACEUTICALS INTERNATIONAL GMBH, Jona (CH)
Filed on Jan. 23, 2023, as Appl. No. 18/100,032.
Application 18/100,032 is a continuation of application No. 17/286,542, granted, now 11,584,779, previously published as PCT/US2019/057122, filed on Oct. 21, 2019.
Claims priority of provisional application 62/856,224, filed on Jun. 3, 2019.
Claims priority of provisional application 62/747,701, filed on Oct. 19, 2018.
Prior Publication US 2023/0167156 A1, Jun. 1, 2023
Int. Cl. C07K 7/64 (2006.01)
CPC C07K 7/645 (2013.01) [C07B 2200/13 (2013.01)] 9 Claims
 
1. A crystalline form of Voclosporin, characterized by data selected from one or more of the following:
(a) a PXRD pattern having peaks at 6.3, 7.0, 8.3, 12.2 and 14.1 degrees 2-theta±0.2 degrees 2-theta;
(b) a PXRD pattern substantially as depicted in FIG. 4;
(c) unit cell parameters at 180 K substantially as follows:
 
 
 
 cell length a 19.6428(6) Å
 
 cell length b 27.9098(8) Å
 
 cell length c 42.4271(12) Å
 
 cell angle alpha 90°
 
 cell angle beta 90º
 
 cell angle gamma 90°
 
 cell volume 23259.7(12) Å3
 
 symmetry cell setting orthorhombic
 
 symmetry space group name P212121; and
 
 
(d) combinations of any two or more of (a), (b) and (c).